ArticleOncotarget2017
Visible-light-sensitive titanium dioxide nanoplatform for tumor-responsive Fe2+ liberating and artemisinin delivery.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 23 citations in OpenAlex.
- Anticancer efficacy of dual-loaded SLNs with Doxorubicin (DOX) and Pterostilbene (PTS): formulation, characterization, and evaluation for breast cancer.Nanomedicine (London, England) · 2025Article
- Current Trends and Advances in Nanoplatforms-Based Imaging for Cancer Diagnosis.Indian journal of microbiology · 2025Article
- A comparative study of sericin and gluten for magnetic nanoparticle-mediated drug delivery to breast cancer cell lines.Scientific reports · 2024Article
- Tween 80 Micelles Loaded with FePharmaceutics · 2024Article
- Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Improved Simulated-Daylight Photodynamic Therapy and Possible Mechanism of Ag-Modified TiOInternational journal of molecular sciences · 2023Article
- Artemisinin-Type Drugs in Tumor Cell Death: Mechanisms, Combination Treatment with Biologics and Nanoparticle Delivery.Pharmaceutics · 2022Review
- HRSC advances · 2021Article
- Recent advances of two-dimensional materials in smart drug delivery nano-systems.Bioactive materials · 2020Review
- Recent Progresses in Cancer Nanotherapeutics Design Using Artemisinins as Free Radical Precursors.Frontiers in chemistry · 2020Review
- Current trends and challenges in cancer management and therapy using designer nanomaterials.Nano convergence · 2019Review
- Antitumor Research on Artemisinin and Its Bioactive Derivatives.Natural products and bioprospecting · 2018Review
- Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery.Advances in cancer research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artemisinin is a kind of Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.